Eligibility Criteria

Funded vaccine will be available from April until 31 December 2018
INFLUVAC® TETRA - for adults and children aged 3 years or older (available from early April)
FLUARIX® TETRA - for children aged under 3 years, i.e. 6–35 months (available from mid April)

Eligibility criteria for FREE seasonal influenza vaccination for 2018:

  • Pregnant women (any trimester)
  • People aged 65 years and older
  • People aged under 65 years with any of the medical conditons listed below
  • Children aged 4 years or under who have been hospitalised for respiratory illness or hve a history of significant respiratory illness

People under 18 years of age living in the:

  • Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board)
  • Kaikoura and Hurunui areas (within the Canterbury District Health Board)
  • who have been displaced from their homes in Edgecumbe and the surrounding region

The following conditions are excluded from funding:

  • asthma not requiring regular preventative therapy
  • hypertension and/or dyslipidaemia without evidence of end-organ disease

Eligible medical conditions for funded influenza vaccine

List of eligible medical conditions for free influenza immunisation (adults and children).

Funded influenza vaccine is available each year for patients who meet
the following criteria as set by PHARMAC:

• all people 65 years of age and over; or
• people under 65 years of age who:
  • have any of the following cardiovascular diseases:
    • ischaemic heart disease, or
    • congestive heart failure, or
    • rheumatic heart disease, or
    • congenital heart disease, or
    • cerebrovascular disease; or
• have either of the following chronic respiratory diseases:               
    • asthma, if on a regular preventative therapy, or
    • other chronic respiratory disease with impaired lung
      function;(a) or
• have diabetes; or
• have chronic renal disease; or
• have any cancer, please refer to the vaccine precaution below#, excluding basal and squamous skin
  cancers if not invasive; or
• have any of the following other conditions:
      • autoimmune disease(b), or
      • immune suppression or immune deficiency, or
      • HIV, or


  • transplant recipients, or
  • neuromuscular and CNS diseases/disorders(c), or
  • haemoglobinopathies(d), or
  • children on long term aspirin, or
  • a cochlear implant, or
  • error of metabolism at risk of major metabolic decompensation, or
  • pre and post splenectomy, or
  • Down syndrome, or
  • pregnant women (any trimester); or
  • children aged four years or under who have been hospitalised for respiratory illness or have a history of
    significant respiratory illness;

Unless meeting the criteria set out above, the following conditions are
excluded from funding:

• asthma not requiring regular preventative therapy,
• hypertension and/or dyslipidaemia without evidence of end-organ

Also refer to the New Zealand Pharmaceutical Schedule on the PHARMAC website

#New influenza vaccination precaution
Influenza vaccination may be contraindicated or need to be delayed for people receiving some new cancer treatments. Please read the information under Contraindications and precautions to receiving influenza vaccine on page 16 for people receiving atezolizumab (Tecentriq®), ipilimumab (Yervoy®), nivolumab (Opdivo®) and pembrolizumab (Keytruda®) and contact the person’s oncologist or 0800 IMMUNE (0800 466 863) for current advice about influenza vaccination for these people BEFORE administering the vaccine.

a. Chronic respiratory diseases may include: chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, emphysema.
b. Autoimmune diseases may include: coeliac disease, Crohns disease, Graves’ disease, Hashimoto’s thyroiditis, lupus, rheumatoid arthritis:
    Immune suppression or immune deficiency includes diseases modifying anti-rheumatic drugs (DMARDS) or targeted biologic therapies.
c. Neuromuscular and CNS diseases/disorders include: celebral palsy, congenital myopathy, epilepsy, hydrocephaly, motor neurone disease,
    multiple sclerosis, muscular dystrophy, myasthenia gravis, Parkinson’s disease.
d. Haemoglobinopathies including: sickle cell anaemia, thalassemia.


Patient eligibility and clinical queries contact
Immunisation Advisory Centre (IMAC)
The University of Auckland
Phone: 0800 IMMUNE (0800 466 863)
Email: 0800immune@auckland.ac.nz

For manual claiming and Payment Queries
Call sector services contact centre on 0800 458 448